Inovio Pharmaceuticals Inc (NASDAQ: INO) on Friday, soared 1.46% from the previous trading day, before settling in for the closing price of $1.37. Within the past 52 weeks, INO’s price has moved between $1.30 and $12.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 22.92% over the past five years. The company achieved an average annual earnings per share of 48.65%. With a float of $50.56 million, this company’s outstanding shares have now reached $50.96 million.
Let’s look at the performance matrix of the company that is accounted for 134 employees. In terms of profitability, gross margin is -636.81%, operating margin of -11541102.4%, and the pretax margin is -20624824.93%.
Inovio Pharmaceuticals Inc (INO) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Inovio Pharmaceuticals Inc is 0.79%, while institutional ownership is 26.69%.
Inovio Pharmaceuticals Inc (INO) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.61 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 48.65% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 39.23% during the next five years compared to 22.92% growth over the previous five years of trading.
Inovio Pharmaceuticals Inc (NASDAQ: INO) Trading Performance Indicators
Inovio Pharmaceuticals Inc (INO) is currently performing well based on its current performance indicators. A quick ratio of 2.63 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 252.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.19, a number that is poised to hit -0.61 in the next quarter and is forecasted to reach -1.78 in one year’s time.
Technical Analysis of Inovio Pharmaceuticals Inc (INO)
Inovio Pharmaceuticals Inc (NASDAQ: INO) saw its 5-day average volume 2.08 million, a positive change from its year-to-date volume of 1.11 million. As of the previous 9 days, the stock’s Stochastic %D was 36.93%.
During the past 100 days, Inovio Pharmaceuticals Inc’s (INO) raw stochastic average was set at 8.65%, which indicates a significant decrease from 9.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1207 in the past 14 days, which was lower than the 0.1248 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8885, while its 200-day Moving Average is $2.7369. Nevertheless, the first resistance level for the watch stands at $1.4333 in the near term. At $1.4767, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.5133. If the price goes on to break the first support level at $1.3533, it is likely to go to the next support level at $1.3167. The third support level lies at $1.2733 if the price breaches the second support level.
Inovio Pharmaceuticals Inc (NASDAQ: INO) Key Stats
Market capitalization of the company is 70.83 million based on 36,674K outstanding shares. Right now, sales total 220 K and income totals -107,250 K. The company made 70 K in profit during its latest quarter, and -19,690 K in sales during its previous quarter.
